With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.57184-25-5,1-(Cyclopropylmethyl)piperazine,as a common compound, the synthetic route is as follows.
57184-25-5, To a solution of 4-(dibenzylamino)cyclohexan-1-one (273, 5 g, 17.0 mmol) and 1- (cyclopropylmethyl)piperazine (276, 2.4 g, 17.1 mmol) in DCM (30 mL) was added HOAc (1 mL). NaHB(OAc)3 (20 g, 94.4 mmol) was then added in portions. After stirring at room temperature for 48 h, the reaction mixture was neutralized with saturated sodium bicarbonatesolution and extracted with DCM (50 mL x 3). The combined organic phases were dried over Mg504 and concentrated in vacuo. The resulting residue was purified by column chromatography to afford (1 r,4r)-N,N-dibenzyl-4-(4-(cyclopropylmethyl)piperazin- 1- yl)cyclohexan-1-amine (277, 670 mg, 1.6 mmol) and (ls,4s)-N,N-dibenzyl-4-(4- (cyclopropylmethyl)piperazin- 1 -yl)cyclohexan- 1-amine (278, 1.2 g, 2.9 mmol).(1R,4R)-N,N-Dibenzyl-4-(4-(cyclopropylmethyl)piperazin- 1-yl)cyclohexan- 1-amine(277): ?H NMR (300 MHz, CDC13): 37.29-7.26 (m, 4H), 7.24-7.18 (m, 4H), 7.15 -7.10 (m,2H), 3.53 (s, 4H), 2.81- 2.60 (m, 6H), 2.44 – 2.36 (m, 2H), 2.29 (d, J= 6.6 Hz, 2H), 1.96 – 1.88(m, 4H), 1.58 – 1.29 (m, 4H), 1.21 – 1.10 (m, 2H), 0.88 – 0.77 (m, 1H), 0.50 – 0.42 (m, 2H),0.10-0.02 (m, 2H).(1S,4S)-N,N-Dibenzyl-4-(4-(cyclopropylmethyl)piperazin- 1-yl)cyclohexan- 1-amine(278): ?H NMR (300 MHz, CDC13): oe 7.29-7.27 (m, 4H), 7.23 -7.18 (m, 4H), 7.14-7.09 (m,2H), 3.57 (s, 4H), 2.96 – 2.49 (m, 8H), 2.40 (d, J= 6.6 Hz, 2H), 2.20 (s, 1H), 1.89 – 1.85 (m,2H), 1.77 – 1.66 (m, 2H), 1.48 – 1.44 (m, 2H), 1.26 – 1.17 (m, 3H), 1.00 – 0.82 (m, 1H), 0.55 -0.49 (m, 2H), 0.16-0.11 (m, 2H).
57184-25-5 1-(Cyclopropylmethyl)piperazine 965875, apiperazines compound, is more and more widely used in various fields.
Reference£º
Patent; G1 THERAPEUTICS, INC.; STRUM, Jay, Copeland; JUNG, David; (250 pag.)WO2018/5860; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics